Celgene Co. (NASDAQ:CELG) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 14,380,412 shares, a growth of 10.3% from the January 12th total of 13,038,301 shares. Based on an average trading volume of 9,042,197 shares, the short-interest ratio is presently 1.6 days. Approximately 1.8% of the shares of the stock are short sold.
Celgene (NASDAQ CELG) traded up $1.49 on Friday, reaching $92.51. 11,078,628 shares of the company traded hands, compared to its average volume of 8,484,788. The company has a market cap of $70,130.00, a PE ratio of 25.63, a P/E/G ratio of 0.68 and a beta of 1.49. Celgene has a 1-year low of $88.32 and a 1-year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.
Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.78 by $0.09. The business had revenue of $3.48 billion for the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 64.14%. The firm’s revenue was up 16.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.61 EPS. equities research analysts predict that Celgene will post 7.68 EPS for the current fiscal year.
In other news, insider Mark J. Alles bought 3,260 shares of the business’s stock in a transaction dated Thursday, February 8th. The stock was bought at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the completion of the purchase, the insider now owns 178,904 shares of the company’s stock, valued at approximately $16,441,277.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.95% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of CELG. BlackRock Inc. lifted its position in Celgene by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock worth $7,366,919,000 after buying an additional 3,084,227 shares in the last quarter. Vanguard Group Inc. lifted its position in Celgene by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock worth $6,951,579,000 after buying an additional 1,610,056 shares in the last quarter. Jennison Associates LLC lifted its position in Celgene by 11.5% during the 3rd quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock worth $2,181,818,000 after buying an additional 1,546,673 shares in the last quarter. FMR LLC lifted its position in Celgene by 5.9% during the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock worth $1,635,643,000 after buying an additional 697,250 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in Celgene by 3.3% during the 2nd quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after buying an additional 349,974 shares in the last quarter. 78.93% of the stock is currently owned by institutional investors and hedge funds.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.